<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03004703</url>
  </required_header>
  <id_info>
    <org_study_id>ASSAIL-MI 2.0</org_study_id>
    <secondary_id>2016-002581-31</secondary_id>
    <nct_id>NCT03004703</nct_id>
  </id_info>
  <brief_title>ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial</brief_title>
  <acronym>ASSAIL-MI</acronym>
  <official_title>ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>South-Eastern Norway Regional Health Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this study is to evaluate the ability of a single administration of
      tocilizumab to reduce myocardial damage in patients presenting with an acute ST-segment
      elevation myocardial infarction (STEMI). Secondary objectives are to assess the impact of
      treatment on: (i) final infarct size, (ii) left ventricular size and function, (iii)
      inflammation, (iv) extracellular matrix remodeling, (v) lipid parameters, (vi) platelet
      activation and additional pro- and anti-thrombotic parameters, and (vii) study drug safety
      and tolerability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myocardial infarction (MI) is a major contributor to morbidity and mortality in the Western
      world. The main determinant of death and complications is infarct size, and limitation of the
      infarct size has therefore been an important objective for strategies to improve outcome. In
      patients presenting with an acute ST segment elevation myocardial infarction (STEMI), urgent
      myocardial reperfusion with percutaneous coronary intervention (PCI) is the most effective
      treatment to this end. However, despite PCI, the morbidity and mortality in patients with
      STEMI remain substantial. This fact suggests that other, adjuvant strategies are required to
      reduce infarct size and improve outcome. The inflammatory cytokine interleukin (IL)-6 is an
      important mediator of plaque destabilisation and rupture in acute coronary syndrome (ACS) and
      may contribute to the ischemia-reperfusion injury succeeding revascularisation. Experimental
      studies suggest that IL-6 inhibition can limit infarct size through anti-inflammatory
      mechanisms.(ref)

      The investigators recently conducted a double blind, placebo controlled trial in 117 patients
      with non-ST segment elevation myocardial infarction (NSTEMI) who presented within 72 hour
      after the onset of chest pain. In this study, a single, intravenous dose of the IL-6
      antagonist tocilizumab reduced the inflammatory activity by more than 50% in the days
      subsequent to the intervention. Importantly, tocilizumab also reduced troponin T (TnT)
      levels, suggesting that patients receiving tocilizumab sustained less myocardial damage than
      patients who received placebo.1

      Interleukin-6 inhibition might limit infarct size through reduced myocardial inflammation,
      but theoretically, it could also inhibit the repair process within the injured area. While
      the recent study suggests that IL-6 inhibition has largely favourable effects in NSTEMI, it
      remains to be seen if similar, beneficial effects can be obtained in patients with STEMI. On
      this background, the investigators want to investigate the effect of tocilizumab in patients
      with acute STEMI. The postulate is that a single dose of tocilizumab (RoActemra®) will have
      favourable effects on infarct size, as assessed by markers of myocardial necrosis and cardiac
      magnetic resonance imaging (CMR), without negative consequences for the repair process in
      these patients. The hypothesis will be tested in a randomised, double blind, placebo
      controlled trial comprising 200 patients with acute STEMI.

      This is a phase 2 study on a new and exciting anti-inflammatory strategy in cardiovascular
      disease. It will be conducted at three experienced, high volume centres in Norway, and will
      target new and yet unmodified mechanisms during myocardial infarction. The ambition is to
      improve the prognosis of patients with ACS, with potential to change clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2017</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint will be the between-group difference in the myocardial salvage index as measured in the acute phase by cardiac magnetic resonance (CMR) imaging with late gadolinium enhancement (LGE).</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The between-group difference in the AUC for Troponin T (TnT) during index hospitalisation</measure>
    <time_frame>24 -72 hours after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The extent of microvascular obstruction as measured by CMR after 3 - 7 days</measure>
    <time_frame>3 - 7 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final infarct size as measured by CMR 6 months after randomisation</measure>
    <time_frame>6 months after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular size as assessed by CMR 6 months after randomisation</measure>
    <time_frame>6 months after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline-adjusted NT-proBNP at 6 months after randomisation</measure>
    <time_frame>6 months after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC of Creatine Kinase-MB (CK-MB) during index hospitalisation</measure>
    <time_frame>24-72 hours after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC of C-reactive protein (CRP) during index hospitalisation</measure>
    <time_frame>24-72 hours after randomisation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Active drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium chloride 0.9%; 100 ml i.v. once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Active drug: Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.</description>
    <arm_group_label>Active drug</arm_group_label>
    <other_name>RoActemra®,</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chloride 0.9%</intervention_name>
    <description>Placebo: Sodium chloride 0.9%; 100 ml i.v. once.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>NaCl 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients will be screened for eligibility upon admittance due to acute STEMI at either
        participating site. All of the following conditions must apply to the prospective patient
        at screening prior to receiving study agent:

          -  New ST elevation at the J-point in two contiguous leads (cut-points: 0.2mV in men and
             &gt;0.15 mV in women in leads V2-V3 and/or &gt;0.1 mV in other leads) in combination with
             symptoms consistent with acute MI.

          -  Presentation within 6 hours of chest pain.

          -  Indication for urgent coronary angiography with intent to reperfuse presumed occluded
             vessel.

          -  Age between 18 and 80 years.

          -  Informed consent obtained and documented according to ICH/GCP, and national/local
             regulations.

        Exclusion Criteria:

        Patients will be excluded from the study if they meet any of the following criteria:

          -  NSTEMI (non-ST segment elevation in ECG).

          -  Left bundle branch block in ECG

          -  History of previous MI

          -  Cardiogenic shock.

          -  Fibrinolytic therapy within 72 hours prior to admission.

          -  Cardiac arrest / ventricular fibrillation.

          -  History of severe renal failure with estimated glomerular filtration rate &lt; 30
             ml/minutes.

          -  Known, current liver disease

          -  History of concurrent inflammatory, biliary obstructive or malignant disease

          -  A history of chronic or concurrent infectious disease, including a history of HIV,
             tuberculosis, or hepatitis B or C.

          -  Known, uncontrolled lower gastrointestinal (GI) disease such as diverticulitis,
             Crohn's disease, ulcerative colitis, or other symptomatic lower GI conditions that
             could predispose to GI perforations

          -  Major surgery within 8 weeks prior or after baseline

          -  History of central nervous system demyelinating or seizure disorders

          -  History of primary or secondary immunodeficiency

          -  Treatment with immunosuppressants other than low dose corticosteroids (equivalent to 5
             mg of prednisone or less) at the time of randomisation

          -  Immunization with a live/attenuated vaccine within 4 weeks prior to baseline

          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
             antibodies or to tocilizumab

          -  Other contraindications to study medication

          -  Pregnancy, possible pregnancy or breast-feeding - women of child-bearing potential or
             breastfeeding mothers cannot participate. A woman is considered of childbearing
             potential following menarche and until becoming post-menopausal unless permanently
             sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy
             and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12
             months without an alternative medical cause.

          -  Contraindications to CMR (pacemaker, CRT, ICD, certain ferromagnetic implants, severe
             claustrophobia, allergy to contrast medium).

          -  Any condition/circumstances believed to interfere with the ability to comply with
             protocol.

          -  Any reason why, in the opinion of the investigator, the patient should not
             participate.

          -  Failure to obtain written, informed consent by patient or next of kin, for instance in
             case of patient death after consent has been provided in oral.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Gullestad, Professor, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bjørn Bendz, Associate Professor, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pål Aukrust, Professor, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Svend Aakhus, Professor, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rune Wiseth, Professor, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Olavs Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Kristian Damaas, Professor, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Olavs Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geir Øystein Andersen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Oslo University Hospital, Ullevål</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nils Einar Kløw, Professor, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Oslo University Hospital, Ullevål</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anders Opdahl, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Oslo University Hospital, Ullevål</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lars Gullestad, Prof, MD, PhD</last_name>
    <phone>+4723070000</phone>
    <email>lars.gullestad@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaspar Broch, MD, PhD</last_name>
    <phone>+4723070000</phone>
    <email>sbbrok@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oslo University Hospital, Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Gullestad, Professor, MD, Phd</last_name>
      <phone>+4723070000</phone>
      <email>lars.gullestad@medisin.uio.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital, Ullevål</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geir Øystein Andersen, MD, PhD</last_name>
      <phone>+4722119101</phone>
      <email>g.o.andersen@medisin.uio.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Olav Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rune Wiseth, MD, PhD</last_name>
      <phone>+4772573000</phone>
      <email>rune.wiseth@stolav.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Kleveland O, Kunszt G, Bratlie M, Ueland T, Broch K, Holte E, Michelsen AE, Bendz B, Amundsen BH, Espevik T, Aakhus S, Damås JK, Aukrust P, Wiseth R, Gullestad L. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J. 2016 Aug 7;37(30):2406-13. doi: 10.1093/eurheartj/ehw171. Epub 2016 May 8.</citation>
    <PMID>27161611</PMID>
  </reference>
  <reference>
    <citation>Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest. 1985 Nov;76(5):1713-9.</citation>
    <PMID>4056048</PMID>
  </reference>
  <reference>
    <citation>Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007 Sep 13;357(11):1121-35. Review.</citation>
    <PMID>17855673</PMID>
  </reference>
  <reference>
    <citation>Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995 Jun 1;91(11):2844-50. Review.</citation>
    <PMID>7758192</PMID>
  </reference>
  <reference>
    <citation>Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005 Apr 21;352(16):1685-95. Review.</citation>
    <PMID>15843671</PMID>
  </reference>
  <reference>
    <citation>Hou T, Tieu BC, Ray S, Recinos Iii A, Cui R, Tilton RG, Brasier AR. Roles of IL-6-gp130 Signaling in Vascular Inflammation. Curr Cardiol Rev. 2008 Aug;4(3):179-92. doi: 10.2174/157340308785160570.</citation>
    <PMID>19936194</PMID>
  </reference>
  <reference>
    <citation>Ritschel VN, Seljeflot I, Arnesen H, Halvorsen S, Eritsland J, Fagerland MW, Andersen GØ. Circulating Levels of IL-6 Receptor and gp130 and Long-Term Clinical Outcomes in ST-Elevation Myocardial Infarction. J Am Heart Assoc. 2016 Jun 13;5(6). pii: e003014. doi: 10.1161/JAHA.115.003014.</citation>
    <PMID>27412895</PMID>
  </reference>
  <reference>
    <citation>Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, André-Fouët X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008 Jul 31;359(5):473-81. doi: 10.1056/NEJMoa071142.</citation>
    <PMID>18669426</PMID>
  </reference>
  <reference>
    <citation>Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, Armstrong PW; COMMA Investigators. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation. 2003 Sep 9;108(10):1184-90. Epub 2003 Aug 18.</citation>
    <PMID>12925454</PMID>
  </reference>
  <reference>
    <citation>Deftereos S, Giannopoulos G, Angelidis C, Alexopoulos N, Filippatos G, Papoutsidakis N, Sianos G, Goudevenos J, Alexopoulos D, Pyrgakis V, Cleman MW, Manolis AS, Tousoulis D, Lekakis J. Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study. Circulation. 2015 Oct 13;132(15):1395-403. doi: 10.1161/CIRCULATIONAHA.115.017611. Epub 2015 Aug 11.</citation>
    <PMID>26265659</PMID>
  </reference>
  <reference>
    <citation>Biasillo G, Leo M, Della Bona R, Biasucci LM. Inflammatory biomarkers and coronary heart disease: from bench to bedside and back. Intern Emerg Med. 2010 Jun;5(3):225-33. doi: 10.1007/s11739-010-0361-1. Epub 2010 Feb 25. Review.</citation>
    <PMID>20182820</PMID>
  </reference>
  <reference>
    <citation>Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003 Sep 30;108(13):1560-6. Epub 2003 Sep 15.</citation>
    <PMID>12975259</PMID>
  </reference>
  <reference>
    <citation>Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs. 2009;69(5):609-32. doi: 10.2165/00003495-200969050-00007. Review.</citation>
    <PMID>19368420</PMID>
  </reference>
  <reference>
    <citation>Eitel I, de Waha S, Wöhrle J, Fuernau G, Lurz P, Pauschinger M, Desch S, Schuler G, Thiele H. Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2014 Sep 23;64(12):1217-26. doi: 10.1016/j.jacc.2014.06.1194.</citation>
    <PMID>25236513</PMID>
  </reference>
  <reference>
    <citation>Erlinge D, Götberg M, Lang I, Holzer M, Noc M, Clemmensen P, Jensen U, Metzler B, James S, Bötker HE, Omerovic E, Engblom H, Carlsson M, Arheden H, Ostlund O, Wallentin L, Harnek J, Olivecrona GK. Rapid endovascular catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. The CHILL-MI trial: a randomized controlled study of the use of central venous catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. J Am Coll Cardiol. 2014 May 13;63(18):1857-65. doi: 10.1016/j.jacc.2013.12.027. Epub 2014 Feb 5.</citation>
    <PMID>24509284</PMID>
  </reference>
  <reference>
    <citation>Atar D, Arheden H, Berdeaux A, Bonnet JL, Carlsson M, Clemmensen P, Cuvier V, Danchin N, Dubois-Randé JL, Engblom H, Erlinge D, Firat H, Halvorsen S, Hansen HS, Hauke W, Heiberg E, Koul S, Larsen AI, Le Corvoisier P, Nordrehaug JE, Paganelli F, Pruss RM, Rousseau H, Schaller S, Sonou G, Tuseth V, Veys J, Vicaut E, Jensen SE. Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. Eur Heart J. 2015 Jan 7;36(2):112-9. doi: 10.1093/eurheartj/ehu331. Epub 2014 Sep 1.</citation>
    <PMID>25179768</PMID>
  </reference>
  <reference>
    <citation>Ibanez B, Macaya C, Sánchez-Brunete V, Pizarro G, Fernández-Friera L, Mateos A, Fernández-Ortiz A, García-Ruiz JM, García-Álvarez A, Iñiguez A, Jiménez-Borreguero J, López-Romero P, Fernández-Jiménez R, Goicolea J, Ruiz-Mateos B, Bastante T, Arias M, Iglesias-Vázquez JA, Rodriguez MD, Escalera N, Acebal C, Cabrera JA, Valenciano J, Pérez de Prado A, Fernández-Campos MJ, Casado I, García-Rubira JC, García-Prieto J, Sanz-Rosa D, Cuellas C, Hernández-Antolín R, Albarrán A, Fernández-Vázquez F, de la Torre-Hernández JM, Pocock S, Sanz G, Fuster V. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. Circulation. 2013 Oct 1;128(14):1495-503. doi: 10.1161/CIRCULATIONAHA.113.003653. Epub 2013 Sep 3.</citation>
    <PMID>24002794</PMID>
  </reference>
  <reference>
    <citation>Eitel I, Stiermaier T, Rommel KP, Fuernau G, Sandri M, Mangner N, Linke A, Erbs S, Lurz P, Boudriot E, Mende M, Desch S, Schuler G, Thiele H. Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized LIPSIA CONDITIONING trial. Eur Heart J. 2015 Nov 21;36(44):3049-57. doi: 10.1093/eurheartj/ehv463. Epub 2015 Sep 17.</citation>
    <PMID>26385956</PMID>
  </reference>
  <reference>
    <citation>Galderisi M, Henein MY, D'hooge J, Sicari R, Badano LP, Zamorano JL, Roelandt JR; European Association of Echocardiography. Recommendations of the European Association of Echocardiography: how to use echo-Doppler in clinical trials: different modalities for different purposes. Eur J Echocardiogr. 2011 May;12(5):339-53. doi: 10.1093/ejechocard/jer051.</citation>
    <PMID>21555455</PMID>
  </reference>
  <reference>
    <citation>Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J. 1992 Oct;124(4):1017-25.</citation>
    <PMID>1529875</PMID>
  </reference>
  <reference>
    <citation>Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Grøgaard HK, Bjørnerheim R, Brekke M, Müller C, Hopp E, Ragnarsson A, Brinchmann JE, Forfang K. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006 Sep 21;355(12):1199-209.</citation>
    <PMID>16990383</PMID>
  </reference>
  <reference>
    <citation>Gibbons RJ, Valeti US, Araoz PA, Jaffe AS. The quantification of infarct size. J Am Coll Cardiol. 2004 Oct 19;44(8):1533-42. Review.</citation>
    <PMID>15489082</PMID>
  </reference>
  <reference>
    <citation>Engblom H, Heiberg E, Erlinge D, Jensen SE, Nordrehaug JE, Dubois-Randé JL, Halvorsen S, Hoffmann P, Koul S, Carlsson M, Atar D, Arheden H. Sample Size in Clinical Cardioprotection Trials Using Myocardial Salvage Index, Infarct Size, or Biochemical Markers as Endpoint. J Am Heart Assoc. 2016 Mar 9;5(3):e002708. doi: 10.1161/JAHA.115.002708.</citation>
    <PMID>26961520</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2016</study_first_submitted>
  <study_first_submitted_qc>December 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2016</study_first_posted>
  <last_update_submitted>May 13, 2018</last_update_submitted>
  <last_update_submitted_qc>May 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Lars Gullestad</investigator_full_name>
    <investigator_title>Profesor</investigator_title>
  </responsible_party>
  <keyword>Interleukin 6</keyword>
  <keyword>Tocilizumab</keyword>
  <keyword>Acute coronary syndrome</keyword>
  <keyword>STEMI</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

